Price
No data yet.
Social Signal Score
Revenue
$2.74B-1.54%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Viehbacher
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 7,500
- Beta
- 0.16
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.95
Financials
Revenue
$2.74B-1.5%Net Income
$97.50M-70.4%EBITDA
$78.20M-91.8%Free Cash Flow
$489.80M-34.1%EPS (diluted)
$0.66-70.3%Shares Outstanding (diluted)
148.70M+0.1%Operating Expenses
$1.21BCash & Debt
$1.28BReturn of Capital
$0.00Revenue by Segment (annual)
$9.62BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.81B | $1.29B | $8.85 |
| 2024 | $9.68B | $1.63B | $11.20 |
| 2023 | $9.84B | $1.16B | $8.02 |
| 2022 | $10.17B | $3.05B | $20.97 |
| 2021 | $10.98B | $1.56B | $10.44 |
| 2020 | $13.44B | $4.00B | $24.86 |
| 2019 | $14.38B | $5.89B | $31.47 |
| 2018 | $13.45B | $4.43B | $21.62 |
| 2017 | $12.27B | $2.54B | $11.94 |
| 2016 | $11.45B | $3.70B | $16.96 |
| 2015 | $10.76B | $3.55B | $15.38 |
| 2014 | $9.70B | $2.93B | $12.42 |
| 2013 | $6.93B | $1.86B | $7.86 |
| 2012 | $5.51B | $1.38B | $5.80 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BIIB's reported EPS growth of 3.3% a year over 13 years.
- EPS in 5 years
- $10.37
- Implied price
- $207.41
- Return from $217.62
- -1.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $103.12 — -52.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -6.7% | -16.7% | -13.4% | -10.5% | -8.0% | -5.7% |
| -1.7% | -12.2% | -8.8% | -5.7% | -3.1% | -0.7% |
| 3.3% | -7.8% | -4.1% | -1.0% | 1.9% | 4.4% |
| 8.3% | -3.3% | 0.5% | 3.8% | 6.8% | 9.4% |
| 13.3% | 1.2% | 5.2% | 8.6% | 11.7% | 14.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
87Social Signal Score
Mentions (1)
- Newszacks.com·5h ago·Negative
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
View source ↗
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $2.03 per share
Typical surprise +22.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$3.60 vs $2.94beat
- Wed, Apr 29$3.57 vs $3.05beat
- Fri, Feb 6$1.99 vs $1.63beat
- Thu, Oct 30$4.81 vs $3.88beat
- Thu, Jul 31$5.47 vs $3.90beat
- Thu, May 1$3.02 vs $2.90beat
Estimates and results for BIIB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIIB officers and directors.
- Bought
- $585
- Sold
- $771k
1 trade
3 trades
- Minor Lloydsold
- Minor Lloydsold
- Murphy Nicolebought
- Singhal Priyasold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.